Background Prior case series indicated a temporal relationship between use of vedolizumab and new-onset spondyloarthritis. Methods We aimed to evaluate the relationship between initiation of vedolizumab and development of new-onset spondyloarthritis in patients with inflammatory bowel disease, through serial clinical evaluation and magnetic resonance imaging. A single-centre prospective observational study of 24 patients with inflammatory bowel disease. Patients were eligible if they had active ulcerative colitis or Crohn’s disease and initiating vedolizumab, had no prior history of arthritis or spondyloarthritis and suitable for undergoing serial magnetic resonance imaging. Clinical evaluation was performed by a rheumatologist prior to first dose of vedolizumab and at weeks 8 and 24 weeks after administration. Axial magnetic resonance imaging was performed at baseline, weeks 8 and 24 and evaluated by a blinded central reader. Results Nine tumour necrosis factor inhibitor-naïve patients (4 male; mean age 53.2 yrs; 6 ulcerative colitis; 3 Crohn’s disease) and eight tumour necrosis factor inhibitor-experienced patients (7 male; mean age 48 yrs; 3 ulcerative colitis; 5 Crohn’s disease) completed all assessments. No patients developed new features of axial arthritis either on clinical or blinded radiological assessment at weeks 8 or 24, nor any features of peripheral spondyloarthritis including inflammatory oligoarthritis, enthesitis, dactylitis, or psoriasis (nail, body, or scalp). Both the tumour necrosis factor inhibitor-naive and tumour necrosis factor inhibitor-experienced patients demonstrated good intestinal response to vedolizumab. Conclusion Initiation of vedolizumab did not induce new features of axial or peripheral spondyloarthritis in tumour necrosis factor inhibitor-experienced or tumour necrosis factor inhibitor-naive patients with inflammatory bowel disease.

中文翻译：

---

P696 开始使用维多珠单抗不会引起炎症性肠病患者新发脊柱关节炎：一项包括风湿病学和盲法影像学评估的前瞻性研究

背景 先前的病例系列表明维多珠单抗的使用与新发脊柱关节炎之间存在时间关系。方法 我们旨在通过系列临床评估和磁共振成像来评估炎症性肠病患者开始使用维多珠单抗与新发脊柱关节炎的发展之间的关系。一项对 24 名炎症性肠病患者进行的单中心前瞻性观察研究。如果患者患有活动性溃疡性结肠炎或克罗恩病并开始使用维多珠单抗，既往没有关节炎或脊柱关节炎病史并且适合接受系列磁共振成像，则符合资格。风湿病学家在首次给予维多珠单抗之前以及给药后第 8 周和第 24 周进行了临床评估。在基线、第 8 周和第 24 周进行轴向磁共振成像，并由盲法中央阅读器进行评估。结果 9 名未接受肿瘤坏死因子抑制剂治疗的患者（4 名男性；平均年龄 53.2 岁；6 名溃疡性结肠炎；3 名克罗恩病）和 8 名接受过肿瘤坏死因子抑制剂治疗的患者（7 名男性；平均年龄 48 岁；3 名溃疡性结肠炎；5 名克罗恩病）疾病）完成了所有评估。在第 8 周或第 24 周时，没有患者在临床或盲法放射学评估中出现中轴关节炎的新特征，也没有出现外周脊柱关节炎的任何特征，包括炎性少关节炎、附着点炎、指趾炎或牛皮癣（指甲、身体或头皮）。未接受肿瘤坏死因子抑制剂治疗和接受过肿瘤坏死因子抑制剂治疗的患者均表现出对维多珠单抗的良好肠道反应。结论 在接受过肿瘤坏死因子抑制剂治疗或未接受过肿瘤坏死因子抑制剂治疗的炎症性肠病患者中，开始使用维多珠单抗不会诱发中轴或外周脊柱关节炎的新特征。